The Effect of Oxytocin on Fear Memory Consolidation Novel Intervention to Prevent Posttraumatic Stress Disorder (PTSD)
|ClinicalTrials.gov Identifier: NCT01466127|
Recruitment Status : Completed
First Posted : November 7, 2011
Results First Posted : April 14, 2017
Last Update Posted : April 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Posttraumatic Stress Disorder||Drug: Oxytocin Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||The Effect of Oxytocin on Fear Memory Consolidation: A Novel Intervention to Prevent PTSD|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
Placebo Comparator: Placebo
Matched nasal spray placebo.
Matched nasal spray placebo
Liquid intranasal oxytocin administered in a nasal spray.
Liquid metered-dose nasal spray, 30 IUs, administered once.
Other Name: Syntocinon
- Differential Skin Conductance Response (SCR) During the First Two Extinction Trials [ Time Frame: Day 2 of Conditioning (1 day post Day 1 of Conditioning) ]Differences in skin conductance response (SCR) between the active vs. placebo conditions trials will be used to assess for the impact of oxytocin on fear acquisition and extinction. We will take a mean of the first two extinction trials to get this measure. Data was gathered in micro-Siemens and then underwent a square root transformation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01466127
|United States, Massachusetts|
|Center for Anxiety and Traumatic Disorders, MGH|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Elizabeth A Hoge, MD||Massachusetts General Hospital|